The Global Health Body Sounds Concern Over Critical Scarcity of Obesity Jabs
Fewer than one in 10 people that would benefit from obesity jabs such as Wegovy have access to them, caution the World Health Organization as it releases its initial recommendations on the medications.
With over a billion people worldwide now obese, it is calling for more widespread and fairer access to this class of drugs.
According to projections, over two billion are projected to be obese by 2030 unless action is taken.
"Our latest guidance affirms that excess weight is a chronic disease that can be managed with thorough and continuous support," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are major barriers to broad access to the injections that can assist patients in reducing considerable weight, says the organization.
GLP-1 Therapy Supply Crisis
Even under the present most favorable outlook, the manufacturing of GLP-1 therapies would only suffice for about 100 million people – less than 10% of eligible patients, as stated by the WHO.
The recommendation urges nations and manufacturers to increase availability, via approaches including patent sharing.
A patent on the active ingredient – the core component of a leading brand – is due to expire in multiple nations in 2026.
The Way Obesity Jabs Work
The injections replicate a body's own hormone to delay gastric emptying, suppress the appetite and increase feelings of fullness so individuals reduce food intake.
Individuals usually see weight reduction after several weeks of beginning the once-weekly jabs.
Studies indicates people may see weight return within a year of discontinuing the medication, as their normal hunger return.
To be overweight or obese elevates your likelihood for contracting diseases, like type 2 diabetes, heart disease, stroke, and specific cancers.
Excess weight concerns people in all nations and was responsible for over three and a half million fatalities worldwide in 2024, as per the WHO.
